In their press statement, Merck said they will submit cladribine for registration in the U.S. and Europe later this year. 默克在其记者发布会上称，在今年晚些时候，将在美国和欧洲提交克拉屈滨的注册申请。
Two groups received different doses of cladribine and one group received fake pills. 其中两组接受不同剂量的克拉屈滨治疗，另一组接受安慰剂治疗。
